Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Dow
Merck
McKesson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

NAFTIN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Naftin patents expire, and what generic alternatives are available?

Naftin is a drug marketed by Sebela Ireland Ltd and is included in three NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has three patent family members in three countries.

The generic ingredient in NAFTIN is naftifine hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.

Drug patent expirations by year for NAFTIN
Drug Prices for NAFTIN

See drug prices for NAFTIN

Recent Clinical Trials for NAFTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Semler Research Center Pvt. Ltd.Phase 3
GenZum Life Sciences LLCPhase 3
Merz Pharmaceuticals, LLCPhase 4

See all NAFTIN clinical trials

Recent Litigation for NAFTIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc.

See all NAFTIN litigation

Pharmacology for NAFTIN
Synonyms for NAFTIN
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethanamine Hydrochloride
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride
(E)-N-CINNAMYL-N-METHYL(1-NAPHTHYLMETHYL)AMINE HYDROCHLORIDE
(E)-N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine- hydrochloride
(E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-Methyl-N-(3-phenyl-2-propen-1-yl)-1-naphthalenemethanamine Hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride
(E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, hydrochloride, (E)-
25UR9N9041
65473-14-5
A835130
AB0013289
AB02353
AC-1120
AC1NQY0T
AK326015
AKOS015895211
AN-15212
API0000683
AS-13296
AW 105-843
AW 105843
AW-105-843
AW-105843
BC679571
BCP07446
C-19785
C08072
C1162
CAS-65473-14-5
CCG-213447
CHEBI:7452
CHEMBL1200493
CS-2730
D00883
DSSTox_CID_25496
DSSTox_GSID_45496
DSSTox_RID_80915
DTXSID2045496
Exoderil
H72N880
H827
HMS1571E08
HY-B0518A
I06-0253
J10185
LS-176455
MFCD00059047
MLS002154136
MolPort-003-666-692
N-Methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride
N-trans-Cinnamyl-N-methyl-(1-naphthylmethyl)amine Hydrochloride
N-trans-Cinnamyl-N-methyl-(1-napphthylmethyl)amine hydrochloride
NAFT-600
naftifin hydrochloride, (E)-isomer
Naftifine (hydrochloride)
Naftifine HCl
NAFTIFINE HYDROCHLORIDE
Naftifine Hydrochloride ,(S)
Naftifine hydrochloride (USP)
Naftifine hydrochloride [USAN:USP]
Naftifine hydrochloride [USAN]
Naftifine hydrochloride, 99%
Naftifine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Naftifine, HCl
Naftifungin
Naftin (TN)
Naftin hydrochloride
NCGC00016908-01
NCGC00179332-03
NSC-760068
NSC760068
Pharmakon1600-01505446
s3156
SCHEMBL41356
SCHEMBL4932462
SMR001233443
SN 105-843
SN 105843
SN-105843
SR-01000838853
SR-01000838853-2
Suadian
SureCN1649698
Tox21_110677
Tox21_110677_1
UNII-25UR9N9041
Paragraph IV (Patent) Challenges for NAFTIN
Tradename Dosage Ingredient NDA Submissiondate
NAFTIN GEL;TOPICAL naftifine hydrochloride 204286 2015-02-04

US Patents and Regulatory Information for NAFTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-002 Jan 13, 2012 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NAFTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd NAFTIN naftifine hydrochloride CREAM;TOPICAL 019599-001 Feb 29, 1988   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990   Start Trial   Start Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 019356-001 Jun 18, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Dow
Boehringer Ingelheim
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.